References: New Treatments for Parkinson’s Disease
- FibonacciMD
- Oct 1, 2025
- 2 min read
References for CME Article
References
[1] Hariz M, Blomstedt P. Deep brain stimulation for Parkinson's disease. J Intern Med. 2022; 292: 764–778. Retrieved from: https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.13541
[2] Stoker TB, Barker RA. Recent developments in the treatment of Parkinson's Disease. F1000Res. 2020;9:F1000 Faculty Rev-862. Published 2020 Jul 31. Retrieved from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7400683/
[3] How many people have Parkinson’s disease? The American Parkinson Disease Association. September 24, 2024. Retrieved from: https://www.apdaparkinson.org/article/parkinsons-disease-registries/
[4] Sivanandy P, et al. Systematic Review on Parkinson’s Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson’s Symptoms. International Journal of Environmental Research and Public Health. 2022; 19(1):364. Retrieved from: https://www.mdpi.com/1660-4601/19/1/364
[5] Parkinson’s Disease Medications. Cleveland Clinic. Last reviewed on 11/09/2023. Retrieved from: https://my.clevelandclinic.org/health/treatments/parkinsons-disease-medications
[6] Antonini A. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease. J Mov Disord. 2009;2(1):4-9. Retrieved from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4027699/
[7] McFarthing K, Prakash N, Simuni T. Clinical Trial Highlights: 1. Gene Therapy For Parkinson's, 2. Phase 3 Study In Focus - Intec Pharma's Accordion Pill, 3. Clinical Trials Resources. J Parkinsons Dis. 2019;9(2):251-264. Retrieved from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6598021/
[8] Keown A. Intec Pharma Crashes as Phase III Parkinson’s Treatment Fails in Comparison Trial. Biospace. July 22, 2019. Retrieved from: https://www.biospace.com/intec-pharma-crashes-as-phase-iii-parkinson-s-treatment-fails-in-comparison-trial
[9] Lobo A. Vaccine for early Parkinson’s showing safety in Phase 2 trial. BioNews. November 18, 2024. Retrieved from: https://parkinsonsnewstoday.com/news/vaccine-early-parkinsons-showing-safety-phase-2-trial/
[10] Bendor JT, Logan TP, Edwards RH. The function of α-synuclein. Neuron. 2013;79(6):1044-1066. Retrieved from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3866954/
[11] Polymeropoulos MH, Lavedan C, Leroy E, et al. : Mutation in the -Synuclein Gene Identified in Families with Parkinson's Disease. Science. 1997;276(5321):2045–7. Retrieved from: https://www.researchgate.net/profile/Aglaia-Athanassiadou/publication/14022561_Mutation_in_the_-Synuclein_Gene_Identified_in_Families_with_Parkinson%27s_Disease/links/58ef92790f7e9b6f82dbb604/Mutation-in-the-Synuclein-Gene-Identified-in-Families-with-Parkinsons-Disease.pdf
[12] Alfaidi M, Barker RA, Kuan WL. An update on immune-based alpha-synuclein trials in Parkinson's disease. J Neurol. 2024;272(1):21. Published 2024 Dec 12. Retrieved from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11638298/
[13] Gorbatyuk OS, Li S, Nash K, et al. In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther. 2010;18(8):1450-1457. Retrieved from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2927065/
[14] Freed CR et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001 Mar 8 344. Retrieved from: https://www.nejm.org/doi/full/10.1056/NEJM200103083441002
[15] Sawamoto, N., Doi, D., Nakanishi, E. et al. Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease. Nature 641, 971–977 (2025). Retrieved from: https://www.nature.com/articles/s41586-025-08700-0#citeas
[16] Tabar, V. et al. Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease. Nature 641, 978–983 (2025). Retrieved from: https://www.nature.com/articles/s41586-025-08845-y
[17] Schuepbach WMM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013; 368(7): 610–622. Retrieved from: https://www.nejm.org/doi/10.1056/NEJMoa1205158
[18] BRAIN Initiative Research Leads to FDA Approval of Adaptive Deep Brain Stimulation for Parkinson’s Disease. NIH. March 06, 2025. Retrieved from: https://braininitiative.nih.gov/news-events/blog/brain-initiative-research-leads-fda-approval-adaptive-deep-brain-stimulation
[19] Stanslaski S et al. Sensing data and methodology from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) clinical trial. NPJ Parkinsons Dis. 2024;10(1):174. Published 2024 Sep 17. Retrieved from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11408616/
[20] Tian X et al. Efficacy and safety of magnetic resonance-guided focused ultrasound for Parkinson’s disease: a systematic review and meta-analysis. Frontiers in Neurology. Volume 14 – 2023. Retrieved from: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1301240/full
[21] Streumer J et al. Does spinal cord stimulation improve gait in Parkinson's disease: A comprehensive review. Parkinsonism & Related Disorders. Volume 109, 2023.Retrieved from: https://www.sciencedirect.com/science/article/pii/S1353802023000548